Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria
Medha Barbhaiya,Stephane Zuily,Yasaman Ahmadzadeh,Mary‐Carmen Amigo,Tadej Avcin,Maria Laura Bertolaccini,D. Ware Branch,Guilherme Jesus,Katrien M. J. Devreese,Camille Frances,David Garcia,Francis Guillemin,Steven R. Levine,Roger A. Levy,Michael D. Lockshin,Thomas L. Ortel,Surya V. Seshan,Maria Tektonidou,Denis Wahl,Rohan Willis,Ray Naden,Karen Costenbader,Doruk Erkan,the New APS Classification Criteria Collaborators,Maria Laura Bertolaccini,Thomas L. Ortel,Nancy Agmon‐Levin,Cassyanne Aguilar,Paula Alba,Oral Alpan,Ales Ambrozic,Zahir Amoura,Danieli Andrade,Luis Andrade,Simone Appenzeller,Bahar Artim Esen,Tatsuya Atsumi,Yackov Berkun,Antonio Cabral,Guillaume Canaud,Ricard Cervera,Pojen Chen,Cecilia Chighizola,Rolando Cimaz,Hannah Cohen,Nathalie Costedoat‐Chalumeau,Mark Crowther,Maria Jose Cuadrado,Philip G. de Groot,Philippe de Moerloose,Ronald Derksen,Reyhan Diz‐Kucukkaya,Thomas Dörner,Paul Fortin,Bill Giannakopoulos,Jose A. Gómez‐Puerta,Emilio B. Gonzalez,Murat Inanc,Gili Kenet,Munther Khamashta,Martin Kriegel,Steven Krilis,Carl Laskin,Patti Massicotte,Gale McCarty,Pier Luigi Meroni,Jamal Mikdashi,Barry Myones,Vittorio Pengo,Michelle Petri,Robert Roubey,Lisa Sammaritano,Giovanni Sanna,Savino Sciascia,Flavio Signorelli,Arzu Soybilgic,Angela Tincani,Scott Woller,Cécile Yelnik,
DOI: https://doi.org/10.1002/acr.24520
2021-09-02
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objectives</h3><p>An international multi‐disciplinary initiative, jointly supported by American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR), is underway to develop new rigorous classification criteria to identify patients with high likelihood of Antiphospholipid Syndrome (APS) for research purposes. We applied an evidence‐ and consensus‐ based approach to identify candidate criteria and develop a hierarchical organization of criteria within domains.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>During Phase I, the APS classification criteria Steering Committee used systematic literature reviews and surveys of international APS physician scientists to generate a comprehensive list of items related to APS. In Phase II, we reviewed the literature, administered surveys, formed domain subcommittees, and used Delphi exercises and nominal group technique to reduce potential APS candidate criteria. Candidate criteria were hierarchically organized into clinical and laboratory domains.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Phase I generated 152 candidate criteria, expanded to 261 items with the addition of subgroups and candidate criteria with potential negative weights. Using iterative item reduction techniques in Phase II, we initially reduced these items to 64 potential candidate criteria organized into ten clinical and laboratory domains. Subsequent item reduction methods resulted in 27 candidate criteria, hierarchically organized into six additive domains (laboratory, macrovascular, microvascular, obstetric, cardiac, and hematologic) for APS classification.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>Using data‐ and consensus‐driven methodology, we identified twenty‐seven APS candidate criteria in six clinical or laboratory domains. In the next phase, the proposed candidate criteria will be used for real‐world case collection and further refined, organized, and weighted to determine an aggregate score and threshold for APS classification.</p></section>
rheumatology